Verification evidence is still being completed.
PDF / print export
Topas Therapeutics GmbH
Hamburg, Germany
- Verified lead
- Hugo Fry
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Antigen-Specific Nanoparticle Therapeutics, Immune Tolerance, and Autoimmune Clinical Development
- Review cycle
- 24 April 2026
- Full address
- Falkenried 88, Haus A, 20251 Hamburg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Topas Therapeutics press release confirming Hugo Fry as Chief Executive Officer from May 2024.
- Editorial note
- Hamburg clinical-stage antigen-specific nanoparticle biotech with a named CEO since May 2024 and a Phase 2a-complete lead in celiac disease, pointing to broader autoimmune applications.
Antigen-Specific Nanoparticle Therapeutics, Immune Tolerance, and Autoimmune Clinical Development
Public CEO disclosure, Documented Phase 2a completion in celiac disease, Published imprint and registered Hamburg address
Hamburg clinical-stage antigen-specific nanoparticle biotech with a named CEO since May 2024 and a Phase 2a-complete lead in celiac disease, pointing to broader autoimmune applications.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Hamburg, Germany
Topas Therapeutics GmbH
Antigen-Specific Nanoparticle Therapeutics, Immune Tolerance, and Autoimmune Clinical Development · Clinical-stage therapeutics development
Hamburg clinical-stage antigen-specific nanoparticle biotech with a named CEO since May 2024 and a Phase 2a-complete lead in celiac disease, pointing to broader autoimmune applications.
- Lead
- Hugo Fry (verified ↗)
- Address
- Falkenried 88, Haus A, 20251 Hamburg, Germany (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage therapeutics development
- Capabilities
- Liver-Targeting Nanoparticle Platform · Antigen-Specific Immune Tolerance Development · Multi-Indication Autoimmune Pipeline
- Founded
- 2016
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Hugo Fry
Chief Executive Officer
Full addressFalkenried 88, Haus A, 20251 Hamburg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Clinical-stage therapeutics development
Hamburg, Germany. Antigen-Specific Nanoparticle Therapeutics, Immune Tolerance, and Autoimmune Clinical Development. Review completed on 24 Apr 2026.
BfArM and EMA for clinical development oversight
Public CEO disclosure, Documented Phase 2a completion in celiac disease, Published imprint and registered Hamburg address
Antigen-Specific Nanoparticle Therapeutics, Immune Tolerance, and Autoimmune Clinical Development
Hamburg clinical-stage antigen-specific nanoparticle biotech with a named CEO since May 2024 and a Phase 2a-complete lead in celiac disease, pointing to broader autoimmune applications.
Editorial note
Topas Therapeutics is a Hamburg nanoparticle-tolerance clinical-stage biotech with a named CEO from May 2024 and a Phase 2a-complete program in celiac disease, with further exploratory programs in autoimmune and inflammatory indications.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Liver-Targeting Nanoparticle Platform
Antigen-Specific Immune Tolerance Development
Multi-Indication Autoimmune Pipeline
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Nanoparticle formulation expertise
Clinical-stage biotech operations
Partner GMP supply relationships
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Topas Therapeutics GmbH located?
- Topas Therapeutics GmbH operates from Falkenried 88, Haus A, 20251 Hamburg, Germany, Hamburg, Germany.
- Who runs Topas Therapeutics GmbH?
- Topas Therapeutics GmbH is led by Hugo Fry, Chief Executive Officer. Verified 24 Apr 2026.
- What does Topas Therapeutics GmbH do?
- Hamburg clinical-stage antigen-specific nanoparticle biotech with a named CEO since May 2024 and a Phase 2a-complete lead in celiac disease, pointing to broader autoimmune applications. Core capabilities: Liver-Targeting Nanoparticle Platform, Antigen-Specific Immune Tolerance Development, Multi-Indication Autoimmune Pipeline.
Editorial context
Related technical briefs
Briefs that name Hamburg as a covered market or city.